Ground-breaking 3D bioprinted tumours aid immunotherapy research
A team of scientists have 3D bioprinted breast cancer tumours and treated them in a new study, offering greater understanding of the disease.
List view / Grid view
A team of scientists have 3D bioprinted breast cancer tumours and treated them in a new study, offering greater understanding of the disease.
Although Cordyceps mushrooms are challenging to cultivate, researchers have shown that they can be grown on edible insects to exploit their strong therapeutic potential.
Trinity College Dublin has developed a new technique that accurately determines the state of macrophages.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
A new study has revealed that activating the RORβ protein could lead to a possible treatment and prevention for osteoarthritis.
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
Using computational screening, researchers have discovered an antibiotic called Dynobactin, that halts the advance of antibiotic-resistant bacteria.
In a petri dish under an environmental condition reminiscent of ALS, the team found that the protein activates a unique pathway inside cells that increases survival and protects endothelial cells from toxic substances in the blood.
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
Clarametyx says the FDA has accepted an IND application for first-in-human trials of CMTX-101, an antibody to treat bacterial pneumonia.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
Potential uses for the study could include repairing spinal cord injuries and a range of other localised injection applications.
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.